Enliven Therapeutics Increases Authorized Common Stock to 200M
Enliven Therapeutics, Inc. held its Annual Meeting of Stockholders on June 9, 2026, where stockholders approved an amendment to increase the authorized shares of common stock from 100,000,000 to 200,000,000. This amendment was effective upon filing. Additionally, stockholders re-elected two Class III Directors, ratified Deloitte & Touche LLP as the independent auditor for 2026, and approved the compensation of named executive officers in an advisory vote. The frequency for future advisory votes on executive compensation was set to annually.
Key Highlights
- Authorized common stock increased from 100,000,000 to 200,000,000 shares.
- Total authorized shares now 210,000,000 (200M common, 10M preferred).
- Richard Fair (50,534,439 votes For) and Lori Kunkel (32,788,330 votes For) re-elected as Class III Directors.
- Deloitte & Touche LLP ratified as independent auditor for fiscal year 2026 (56,119,493 votes For).
- Advisory vote on named executive officer compensation approved (47,572,153 votes For).
- Annual frequency approved for future advisory votes on executive compensation (49,028,648 votes for one year).
Price Impact
More from ELVN
Enliven Therapeutics Prices Upsized Public Offering for $400M Gross
Enliven Therapeutics Reports Positive Phase 1 Data for ELVN-001; FDA Aligns on Phase 3 Dose
Enliven Therapeutics Q1 Net Loss Narrows to $23.6M; Cash $132.2M